Summit Therapeutics Inc SMMT 深 沪
等待开盘 06-26 09:30:00 美东时间
14.20
-0.050
-0.35%
华盛通- 最 高14.81
- 今 开14.25
- 成交量 368.45万股
- 最 低 13.70
- 昨 收 14.25
- 总市值 139.33万
- 52周最高 30.978
- 市盈率 静 --
- 换手率 3755.02%
- 52周最低 12.5501
- 委 比 51.62%
- 总股本 9.81万
- 历史最高 36.91
- 量 比 0.59
- 振 幅 7.79%
- 历史最低 0.66
- 每 手 1
- 风险率 3.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Downgrades Summit Therapeutics to Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Summit Therapeutics (NASDAQ:SMMT) from Buy to Neutral.
05-22 18:41
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results
Stocks traded mixed, with Dow down 0.1% but NASDAQ up 1.06%. Chevron reported mixed Q1 results. Esperion, Five9, Atlassian soared while Summit, Crescent, LendingTree fell.
05-02 03:39
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue
US stocks traded higher, with the Nasdaq up 1%. Dow up 0.05%, Nasdaq up 1.13%, S&P 500 up 0.58%. Tech shares jumped 1.6%, energy stocks fell 1.5%.
05-02 02:15
Summit Therapeutics Stock Dips After Q1 Financial Report
Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know.
05-01 23:12
Earnings Scheduled For February 23, 2026
Companies Reporting Before The Bell • Domino's Pizza (NASDAQ:DPZ) is likely to ...
02-23 19:11
Preview: Summit Therapeutics's Earnings
Summit Therapeutics (NASDAQ:SMMT) will release its quarterly earnings report on...
02-20 22:02
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway
The FDA accepted Summit Therapeutics' application for its lung cancer drug ivonescimab, setting a November 2026 decision date after positive Phase 3 trial results.
01-30 01:28
Alpha Buying: Managing Biotech Risk With Insider Clues
Biotech stocks have a way of making smart people do dumb things. It starts inno...
01-16 00:32
PD-(L)1/VEGF赛道攻坚，依沃西冲击首个海外适应症
21世纪经济报道记者 韩利明 当地时间10月20日，Summit Therapeutics（纳斯达克股票代码：SMMT）在2025年三季度财报中宣布，将于20...
2025-10-22 11:55
Summit Thera三季度每股亏损0.13美元
美股周一早盘，生物制药企业Summit Therapeutics（SMMT）股价下跌4.9%，此前该公司报告第三季度每股亏损0.13美元，未达预期。尽管盈利不及预期，公司现金储备依然雄厚，支持其持续的战略计划。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-10-20 23:29
